• Media
  • Contact
  • Careers
  • About Us
    • About Us
    • Management
    • Clinical Advisors
  • Science
  • Patients
    • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Investors
  • Media
    • Press Releases
    • Events & Presentations
  • Contact
  • Careers
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients With Moderate to Severe COVID-19  Learn More...

Innovation for Healthier Lives

For Patients
For Physicians

Our Mission

ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.

Learn about our Product Candidates

Abivertinib
Learn More

AC0058
Learn More

AC0002
Learn More

AC0078
Learn More

  • About Us
    • Clinical Advisors
    • Management
  • Science
  • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Investors
  • Media
    • Press Releases
    • Events & Presentations
  • Careers
  • Contact
    • Media & Investor Relations
    • Business Development
    • Headquarters
    • Facilities
© 2021 ACEA Therapeutics | All Rights Reserved | Privacy Policy
  • About Us
    • About Us
    • Management
    • Clinical Advisors
  • Science
  • Patients
    • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Investors
  • Media
    • Press Releases
    • Events & Presentations
  • Contact
  • Careers